Introduction
Gastric carcinoma is ranked as the world's second leading cause of cancer mortality next to lung cancer, with an estimated 800 000 new cases and 650 000 deaths per year [1] . Growing evidence suggests that chemotherapy may improve disease-free intervals and overall survival [2, 3] . In this regard, the current high rates of recurrence and subsequent poor survival have prompted the ever-increasing use of multimodal strategies. Therefore, further studies are necessary to refi ne the list of molecular markers and to identify novel markers for prognostic and predictive purposes.
Differences in kinetic parameters related to DNA replication licensing may be candidates for growth control and, therefore, of importance in carcinogenesis. The initiation of eukaryotic DNA replication is precisely controlled through a core set of licensing factors, including Orc1-6, Cdc6, Cdt1, and minichromosome maintenance (MCM) 2, for seven proteins, during S phase [4] [5] [6] . Licensed replication origins are activated by cyclin-dependent kinases, resulting in the unwinding of the DNA helix and the initiation of DNA synthesis [7] . Replication initiation is tightly coupled to removal of the license, which prevents relicensing after origin fi ring until mitosis. This step is critical, as origins must fi re once, and once only, in each cell cycle, to ensure genomic stability [8, 9] .
The overexpression of MCM2 protein was reported in a variety of malignant neoplasms in our previous studies, and a possible prognostic signifi cance of the expression in oral and bronchial carcinomas, as well as in soft tumors, was confi rmed [10] [11] [12] . It is of interest that MCM2 protein has higher sensitivity than Ki-67 for proliferation in cycling and noncycling cells that possess proliferative potential, and this implies that MCM2 protein could be a promising novel marker for proliferation in such cells.
Only a few studies have examined MCM2 expression in gastric carcinoma, and the prognostic signifi cance of this expression has never been analyzed [13, 14] . The aim of this study was to determine whether the expression of this novel licensing protein, MCM2, might be useful in predicting the potential for tumor proliferation and the outcome for stage III gastric carcinoma, which frequently metastasizes to the liver and peritoneum, and for which the prognosis remains unfavorable [15] .
Patients, materials, and methods

Cell lines and Western blotting
The expression of MCM2 was examined in eight human gastric carcinoma cell lines: MKN-1, -7, -28, -45, -74, TMK-1, KATO-III, and HSC-39. All of the cell lines were cultured in Dulbecco's modifi ed Eagle's medium supplemented with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY, USA), 100 U/ml penicillin, 100 µg/ml streptomycin, and 292 µg/ml Lglutamine, at 37 °C in a humidifi ed atmosphere with 5% CO 2 in air.
The subconfl uent cells were rinsed in phosphatebuffered saline (PBS) and solubilized in lysis buffer (150 mM NaCl; 20 mM Tris-HCl, pH 7.4; 0.1% sodium dodecyl sulfate [SDS]; 1% sodium deoxycholate; and 1% Triton X-100, containing a mixture of proteinase inhibitors [5 µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fl uoride, and 1 mg/ml trypsin inhibitor]) for 60 min on ice. Lysates were centrifuged at 12 000 rpm for 5 min. The protein concentrations were determined with the Bradford protein assay (BioRad Laboratories, Hercules, CA, USA), using bovine serum albumin as the standard. Equal amounts (30 µg) of proteins were resolved by electrophoresis on 7.5% polyacrylamide gel and electrotransferred to a polyvinylidene difl uoride fi lter membrane (Immobilon; Millipore, Waltham, MA, USA). After the blocking of nonspecifi c binding with 10% skimmed milk in PBS for 1 h at room temperature, the blotted membrane was incubated with anti-MCM2 (diluted 1: 5) mouse monoclonal antibodies, which were generated in our laboratory, and which detect the N-terminal 13 amino acids of MCM2 (amino acids 15-27, LTSSPGRSSRRTD) [10] [11] [12] . Blots were developed with peroxidase-labeled antimouse IgG antibody (1: 1000; MBL, Nagoya, Japan), using enhanced chemiluminescence (ECL Detection System; Amersham Pharmacia Biotech, Amersham, UK).
Tissue specimens
Primary stage III gastric carcinoma specimens of 103 patients were divided into intestinal and diffuse types according to the Lauren classifi cation [16] . Intestinaltype carcinomas were obtained from 60 patients and diffuse-type carcinomas were obtained from 43 patients who had undergone curative gastrectomy at the Department of Surgical Oncology, Tottori University and Yonago Medical Center Hospital. No patient had received preoperative chemotherapy or radiotherapy. Histological diagnoses were made on hematoxylin and eosin (H&E) tissue sections, according to the Japanese classifi cation of gastric carcinoma [17] . All the patients had undergone distal, proximal, or total gastrectomy, with the dissection of level 1 and 2 regional lymph nodes. The follow-up period for survivors was 1-161 months (median, 41 months) after surgery. Informed consent was obtained from all subjects and/or their guardians. This study was approved by the Institutional Review Board at Tottori University, Faculty of Medicine.
Immunohistochemistry
Tissue sections (3 µm) were cut from formalin-fi xed, paraffi n-embedded tissue blocks and put on microscope slides with a silane coat. They were dewaxed in xylene, rehydrated through a graded series of ethanol solutions, and rinsed in distilled water for 5 min. Then, for antigen retrieval, sections were microwaved in 0.01 mol/l sodium citrate buffer (pH 6.0) for 20 min at 95 °C, using a microwave processor (Model MI-77; Azumaya, Tokyo, Japan), and immersed in 0.3% hydrogen peroxide in methanol for 30 min, to block endogenous peroxidase. After being rinsed in PBS for 5 min, the slides were preblocked with a solution of 2 % normal rabbit serum at room temperature for 20 min, and incubated at 4 °C overnight with mouse monoclonal antibodies, as follows: anti-MCM2 antibody, anti-Ki-67 antibody (MIB-1, 1: 50; Dako, Glostrup, Denmark), and anti-p53 (1: 50; Dako). A subsequent reaction was initiated by the streptavidin-biotin-peroxidase complex technique (SAB method), using a Histofi ne SAB-PO (M) Immunohistochemical Staining Kit (Nichirei, Tokyo, Japan). The immunoreaction was visualized with 0.2 mg/ml 3, 3′-diaminobenzidine tetrahydrochloride and 20 µl/dl hydrogen peroxide in 0.05 M Tris-HCl buffer (pH 7.6). Finally, the slides were counterstained with hematoxylin.
Evaluation of MCM2 and Ki-67 labeling indices (LIs) and p53 expression
To evaluate MCM2, Ki-67, and p53 expression levels, positively stained tumor-cell nuclei were counted in the most frequently and distinctly labeled areas, containing the periphery and center, and superfi cial and invasive front. Counts were performed in high-magnifi cation fi elds using the FLOVEL Image Filing System FlvFs (FLOVEL, Tachikawa, Japan). LIs were expressed as the percentage of positively stained cells based on a count of at least 500 tumor cells. The proliferative cells in non-neoplastic mucosa adjacent to carcinoma served as a reliable internal positive control for MCM2 and Ki-67. Lymphoid follicles served as an internal negative control, although only a few lymphoid cells showed immunoreactivity. p53 immunoreactivity was observed in the nuclei of gastric carcinoma cells. All cases were judged to have high expression of p53 when the LI of p53 was more than 10%.
Double-labeling immunofl uorescence
In order to examine the differential expression of MCM2 and Ki-67 in individual specimens, doublelabeling immunofl uorescence experiments were performed on paraffi n-embedded tissue sections that were deparaffi nized, immersed in 10 mM sodium citrate buffer, and microwaved at 95 °C for 20 min. Subsequently, blocking was carried out with 10% normal FBS for 15 min. The sections were then incubated overnight at 4 °C with a mixture of goat anti-MCM2 polyclonal antibody (1: 100; Santa Cruz Biotechnology, Heidelberg, Germany) and anti-Ki-67 antibody (1: 50). Then, they were incubated for 1 h with rabbit anti-goat IgG (Nichirei), and for 6 h at 4 °C with a mixture of AlexaFluor-488-conjugated anti-rabbit antibody diluted 1: 200, and Alexa-Fluor-546-conjugated anti-mouse antibody diluted 1: 200 (Molecular Probes, Eugene, OR, USA). After the sections were washed, immunoreactivity was observed with a fl uorescence microscope (Eclipse E800; Nikon, Tokyo, Japan).
Statistical analysis
The association of factors was evaluated by the χ 2 test. The signifi cance of differences among means was determined by Student's t-test or the Mann-Whitney U-test. Survival rates were estimated by the Kaplan-Meier method, and statistical analysis was carried out by the log-rank test for equality of the survival curves. A Cox proportional hazards model for the risk ratio was used to evaluate survival in a multivariate analysis. The level of signifi cance was set at P < 0.05.
Results
MCM2 expression in human gastric carcinoma cell lines
We examined the expression of MCM2 in eight gastric carcinoma cell lines by Western blotting. Figure 1 shows the expression of MCM2 protein in all the cell lines, with a specifi c single band at 130 kD, which indicates the specifi city of the anti-MCM2 antibody (2H10) used in this study.
MCM2 and Ki-67 expression in gastric mucosa and carcinoma
As shown in Fig. 2, MCM2 and Ki-67 were predominantly localized in the nuclei of cells located in the proliferative zone of non-neoplastic mucosa. In contrast, no specifi c distribution of cells positive for MCM2 and Ki-67 was noted in gastric carcinoma (Fig. 3) . In order to examine the expression patterns of MCM2 and Ki-67 in carcinoma cells simultaneously, doublelabeling immunofl uorescence experiments were conducted (Fig. 4) . All the cells expressing Ki-67 (Fig. 4 , green) also expressed MCM2 (Fig. 4, red) , and this coexpression gave a yellow signal. No cells showing only green fl uorescence were observed among the carcinoma cells, except for mitotic cells that showed immunoreactivity for Ki-67, but not for MCM2. There were variable numbers of MCM2-positive and Ki-67-negative tumor cells with red signals (Fig. 4) .
In the 103 stage III gastric carcinomas, the mean MCM2 LI in the 60 intestinal-type carcinomas was 69.1 ± 11.8% (range, 38.7% to 91.4%), and the mean MCM2 LI in the 43 diffuse-type carcinomas was 43.7 ± 9.90% (range, 20.1% to 65.2%); the value being signifi cantly higher in the former than in the latter (P < 0.001). The mean Ki-67 LI in the 60 intestinal-type carcinomas was 48.2 ± 14.6% (range, 14.0% to 79.5%) and the mean Ki-67 LI in the 43 diffuse-type carcinomas was 24.9 ± 11.0% (range, 5.3% to 46.5%) the value being signifi cantly higher in the former than in the latter (P < 0.001; Table 1 ). The mean LI was signifi cantly higher in MCM2-positive than in Ki-67-positive tumor cells, regardless of histological type. The relationship between the MCM2 and Ki-67 LIs in gastric carcinoma cells is shown in Fig.  5 . A scatter plot indicated that the relationship between the MCM2 and Ki-67 LIs could be modeled as linear. A signifi cant correlation was observed between the MCM2 and Ki-67 LIs (P < 0.0001; Fig. 5 ).
Correlation of MCM2 and Ki67 LIs with clinicopathological characteristics and p53 expression
The relationship between the MCM2 and KI-67 LIs and clinicopathological characteristics and p53 expression in gastric carcinoma is summarized in Tables 2 and 3 . A comparison of LIs and clinicopathological characteristics for each marker in the intestinal-and diffuse-type carcinomas revealed no signifi cant associations with sex, age, histological type, tumor status, lymph node status, lymphatic invasion, or blood vessel invasion.
The mean MCM2 LI was 67.8 ± 12.2% in the intestinal-type carcinomas with high expression of p53 (n = 23) and it was 70.0 ± 11.7% in those with low expression of p53 (n = 37), the difference not being signifi cant (P = 0.50). Similarly, in the diffuse carcinomas with high expression of p53 (n = 20), the mean MCM2 LI was 42.6 ± 11.6% and it was 44.8 ± 8.23% in those with low expression of p53 (n = 23), the difference also not being signifi cant (P = 0.13; Tables 2 and 3) . Thus, no correlation was noted between p53 expression and mean MCM2 LI.
Prognostic analysis
The overall 5-year survival rates were 47% in the 60 patients with stage III intestinal-type gastric carcinoma and 46% in the 43 patients with diffuse-type gastric carcinoma (data not shown). The cutoff level of the MCM2 LI in carcinoma cells was set at 69.0 % for intestinal-type carcinoma (high, n = 30 vs low, n = 30) and at 44.0 % for the diffuse type (high, n = 23 vs low n = 20), with the values being almost at the median. Similarly, the cutoff level of the Ki-67 LI in carcinoma cells was set at 49.0% (high, n = 30 vs low, n = 30) for intestinal-type carcinoma and at 24.7% (high, n = 21 vs low, n = 22) for the diffuse type, respectively (data not shown).
Kaplan-Meier survival curves showed that there was no signifi cant correlation between MCM2 expression and survival rate in the patients with intestinal-type carcinoma (P = 0.25; Fig. 6A ). On the other hand, in the 23 patients with diffuse-type carcinoma with higher MCM2 expression, the prognosis was signifi cantly poorer than that in the 20 patients with lower MCM2 expression (P < 0.05; Fig. 6B ). The Ki-67 LI did not correlate with survival in either the patients with intestinal-type (P = 0.53; Fig. 6C ) or in the patients with diffuse-type (P = 0.38) carcinomas (Fig. 6D) . Multivariate analysis using the Cox model revealed that MCM2 expression and age were independent prognostic factors in the patients with diffuse-type carcinomas (P = 0.035 and P = 0.036, respectively; Table 4 ).
Discussion
The new marker MCM2 opens the possibility of evaluating the proliferative activity in a variety of human tumors. MCM2 protein detected by immunohistochemistry can predict the survival of patients with oral or esophageal squamous cell carcinoma [10, 18] , non-small cell lung cancer [11] , breast cancer [19] , brain tumor [20, 21] , prostate cancer [22] , renal cell carcinoma [23] , and bladder carcinoma [24] . There have been, however, only a few studies of MCM2 for the assessment of proliferative activity in gastric carcinomas [7, 8] .
We clearly demonstrated the nuclear expression of MCM2 in human gastric mucosa and carcinoma using a specifi c anti-MCM2 antibody (2H10). With respect to the expression of MCM2 in normal human stomach tissues, MCM2 expression, as well that of Ki-67, was found in the lower half of the gastric pit, which corresponds to the generative zone. Kato et al. [18] reported that MCM2-positive cells were detected in the parabasal layers in human esophageal mucosa. These results suggest that MCM2, as well as Ki-67, is a marker of proliferative cells in human gastric mucosa. Of note, in the present study, MCM2-positive cells were seen sporadically in gastric carcinoma. The LI of MCM2 was signifi cantly associated with that of Ki-67 in gastric carcinoma, but the MCM2 LI was considerably higher. These results are consistent with those of previous studies [11, 18, 25] . Double-labeling immunofl uorescence clearly demonstrated that MCM2-positive and Ki-67-negative cells were frequently observed in gastric carcinoma, although mitotic cells did not show MCM2 expression. It is known that Ki-67 is absent in early G1 phase [26] . Thus, we consider that MCM2 expression is seen throughout the cell cycle, except for mitosis and G0 phase, while Ki67 expression is seen from late G1 phase to the mitotic phase. It is also suggested that Ki-67 is expressed for a shorter interval of the cell cycle than MCM2 is. Many studies have demonstrated a correlation between the expression of Ki-67 and the number of proliferating cells [27] , although the biological function of the Ki-67 antigen remains largely unknown, and the molecule might be not essential for cell proliferation [28, 29] . The expression level of the Ki-67 antigen can be altered by external factors, such as nutrient deprivation [30] . We also considered that the superior sensitivity of MCM2 over Ki-67 resides in the fact that MCM2 identifi es not only cycling cells but also noncycling cells with proliferative potential [9] . Interestingly, the replication phenotype, Ki-67-negative but MCM-positive, is exhibited by premenopausal breast and primary oocytes that retain proliferative capacity and can rapidly respond to growth stimuli [9] . Gastric cancer can be divided into diffuse and intestinal types, according to the Lauren classifi cation [16] . Intestinal carcinomas form recognizable glands that range in histology from tub1 to por1. Diffuse carcinoma consists of poorly cohesive cells diffusely infi ltrating the gastric wall, with little or no gland formation. The differences in Ki-67 LIs between the intestinal and diffuse types appear to be very striking compared to the results in previous reports. The striking difference might be due to the method we used for the evaluation of LIs. Counts were performed in high-magnifi cation fi elds using the FLOVEL Image Filing System FlvFs. With this system, for the evaluation of LIs, we were able to exclude any stromal or infl ammatory cells in the fi eld more precisely than with systems used in other studies.
The present study confi rmed signifi cantly higher LIs for both MCM2 and Ki-67 in the intestinal-type than in the diffuse-type of stage III gastric carcinomas. Some studies have shown that gastric cancer of the intestinal type had signifi cantly higher proliferative index values, using either Ki-67 [31, 32] or proliferating cell nuclear antigen (PCNA) [33] . This fi nding was consistent with our results, as we found a correlation between tumor cell proliferation and histological type according to the Lauren classifi cation. In general, diffuse-type carcinoma is considered to be more malignant than its intestinaltype counterpart, with early invasion into the muscularis propria and lymphatic vessels, and metastasis to the lymph nodes [34] . Ikeda et al. [32] reported a relationship between the apoptotic index and the Ki-67 LI in human gastric carcinoma. Their report indicated that intestinal-type gastric carcinoma had a signifi cantly higher apoptotic index as well as a signifi cantly higher Ki-67 LI than the diffuse type. Factors other than the growth fraction (e.g., apoptosis and cell adhesion [35] ) may well infl uence the aggressiveness and dissemination of tumors.
In our present study, although MCM2 expression was signifi cantly associated with Ki-67 in the 43 diffuse-type gastric carcinomas, the survival rate, calculated by the Kaplan-Meier method, revealed a signifi cant inverse correlation between prognosis and the expression of MCM2, whereas the expression of Ki-67 showed no correlation with prognosis. However, MCM2 expression did not correlate with any clinicopathological factors, e.g., lymph node status and vascular invasion, in spite of MCM2 contributing to poor prognosis. This contradiction might be explained, in part, by the fact that our examination focused on only stage III gastric carcinoma. In other words, MCM2 expression might be a more critical factor than any other clinicopathological factors in gastric carcinoma. Taken together, these data suggested that MCM2 was more useful as a prognostic marker than Ki-67 in stage III diffuse-type gastric carcinoma.
We found that age was also an independent prognostic indicator for patients with diffuse-type gastric carcinoma. It has been suggested that age itself is not an independent prognostic survival factor for patients with gastric carcinoma [36, 37] . It is possible that the infl uence of morbidity factors associated with the aging process on the long-term results might have represented a bias in this study.
Finally, it is worthwhile to touch upon the relationship between MCM2 and p53 expression. Cell-cycleregulated gene sets overlap with proliferation signatures in tumor samples [38] . Gastric cancer cells with overexpression of mutated p53 protein may have high proliferative activity [39] . Kodani et al. [10] have reported that the expression of MCM2 is signifi cantly higher in oral squamous cell carcinomas with high expression of p53 compared to those with low p53 expression, which suggests that MCM2 is correlated with p53 expression. However, in the present study, we could not confi rm a signifi cant relationship between MCM2 and p53 LIs in either intestinal-or diffuse-type carcinoma. Further studies are needed to clarify the pathobiological significance of any relationship between MCM2 and p53 in human gastric carcinoma.
